Thus, the previous evidence supports the hypothesis that the TNFR1-selective inhibitors, which do not affect the immunomodulatory functions of TNFR2, have the potential to be used as therapy for diverse inflammatory diseases, including lung affections as COVID-19. The gene discussed is TNFRSF1A; the disease is COVID-19.